Ƶ

Ozempic OK'd for CV Prevention; LDL Drug Pricing; Lyme Disease Heart Tx

— Recent developments of interest in cardiovascular medicine

Ƶ MedicalToday

Weekly injectable diabetes drug for use in adults with type 2 diabetes and known heart disease, Novo Nordisk announced. The pill formulation (Rybelsus) also got a cardiovascular-safety label update.

came at the JP Morgan conference in San Francisco over insurers' effective blockade of what had been hoped to be blockbusters. But the inclisiran folks were optimistic and bempedoic acid's makers said they would price it around $3,600 a year, "like they were priced 5-10 years ago," if the impending FDA approval goes through. (Endpoint News)

While cholesterol-lowering drug inclisiran is yet to be approved, the U.K. national health service already . (CNBC)

Removing transcatheter aortic valves after they have been in for more than a year required ," while 40% needed aortic root repair. (Journal of Thoracic and Cardiovascular Surgery)

Another fish oil pill flopped: The failed to reduce triglycerides in the pivotal TRILOGY-1 trial in patients with hypertriglyceridemia on statin therapy, with a larger-than-expected placebo response, Ascasti Pharma announced.

are hitting even traditionally healthy areas, like Colorado. (Wall Street Journal)

A young, marathon-running mom had to have a . (Today)

are picking up steam in the U.S. with a clinical trial aimed at FDA approval of a warm perfusion system. (STAT News)

, researchers reported in the European Journal of Preventive Cardiology. (ESCardio.org)

European and African interventionalists are trying out a in a 60-patient study and possible . (Cath Lab Digest, MassDevice)

Another blow for peripheral : A meta-analysis turned up more all-cause death and major amputation when used for chronic limb ischemia below the knee, and "non-target paclitaxel embolization is a plausible mechanism." (Journal of Vascular and Interventional Radiology)

Cardiology ranks , a survey found. (Cardiovascular Business)